LeonaBio 경영진

경영진 기준 점검 3/4

LeonaBio CEO는 Mark Litton, Oct2021 에 임명되었습니다 의 임기는 4.58 년입니다. 총 연간 보상은 $1.42M, 43.9% 급여 및 56.1% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $604.33K 가치에 해당하는 회사 주식의 0.64% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.7 년과 4.3 년입니다.

핵심 정보

Mark Litton

최고경영자

US$1.4m

총 보수

CEO 급여 비율	43.90%
CEO 재임 기간	4.6yrs
CEO 지분 보유율	0.6%
경영진 평균 재임 기간	2.7yrs
이사회 평균 재임 기간	4.3yrs

최근 경영진 업데이트

Recent updates

분석 기사 • Feb 16

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Athira Pharma (NASDAQ:ATHA) said an independent data monitoring committee recommended to continue a phase 2/3 trial of fosgonimeton (ATH-1017) to treat patients with mild-to-moderate Alzheimer's disease (AD). The committee made the recommended after an interim efficacy and futility analysis of the study, dubbed LIFT-AD, the company added. In addition, the panel decided that, with the additional enrollment of fewer than 150 patients for a total enrollment of less than 300 people without background therapy (acetylcholinesterase inhibitors), the trial will be well powered for the main goal given the preliminary effect size seen, according to the company. The main goal of the trial is Global Statistical Test, a tool for measuring cognition and function. Athira noted that data from a phase 2 study called ACT-AD had showed a favorable safety profile and suggested positive effects on measures of cognition, function and neurodegeneration in patients taking fosgonimeton without background therapy. ATHA +2.49% to $3.29 premarket Oct. 17

Seeking Alpha • Aug 15

Athira Pharma GAAP EPS of -$0.65

Athira Pharma press release (NASDAQ:ATHA): Q2 GAAP EPS of -$0.65. Cash, cash equivalents and investments were $282.2 million as of June 30, 2022, compared with $319.7 million as of December 31, 2021.

분석 기사 • Aug 09

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Jun 22

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Athira Pharma has just read out first Phase 2 results in one of two Alzheimer’s trials. Its drug candidate ATH-1017 targets the HGF/MET pathway, a unique approach which has led to promising Phase 1 data. The readout shows efficacy in a subgroup, underlining validity of the proposed pathway and drug candidate ATH-1017, and I expected this would happen. The company's shares are falling severely on the primary endpoint miss. Simply stated, if the primary endpoint would have been cognition in the monotherapy group, then the results would have been seen as successful, which is why I believe there is potential to be a new Alzheimer's drug in the making here.

분석 기사 • May 08

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

분석 기사 • Jan 11

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Jun 29

Athira Pharma: What, Exactly, Did The CEO Do?

CEO Leen Kawas is on leave because she is pending review for allegations of scientific misconduct. The science in question relates to Athira's core work in Alzheimer's. How strongly they are related will determine Athira's future.

분석 기사 • May 24

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

분석 기사 • Feb 08

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

분석 기사 • Dec 18

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

The big shareholder groups in Athira Pharma, Inc. ( NASDAQ:ATHA ) have power over the company. Institutions often own...

CEO 보수 분석

Mark Litton의 보수는 LeonaBio의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Mar 31 2026	n/a	n/a	-US$129m
Dec 31 2025	US$1m	US$625k	-US$106m
Sep 30 2025	n/a	n/a	-US$38m
Jun 30 2025	n/a	n/a	-US$60m
Mar 31 2025	n/a	n/a	-US$80m
Dec 31 2024	US$3m	US$625k	-US$97m
Sep 30 2024	n/a	n/a	-US$109m
Jun 30 2024	n/a	n/a	-US$113m
Mar 31 2024	n/a	n/a	-US$116m
Dec 31 2023	US$2m	US$585k	-US$118m
Sep 30 2023	n/a	n/a	-US$121m
Jun 30 2023	n/a	n/a	-US$108m
Mar 31 2023	n/a	n/a	-US$102m
Dec 31 2022	US$4m	US$543k	-US$96m
Sep 30 2022	n/a	n/a	-US$82m
Jun 30 2022	n/a	n/a	-US$77m
Mar 31 2022	n/a	n/a	-US$67m
Dec 31 2021	US$3m	US$450k	-US$55m
Sep 30 2021	n/a	n/a	-US$46m
Jun 30 2021	n/a	n/a	-US$39m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	n/a	n/a	-US$20m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$6m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$204k	US$12k	-US$5m

보상 대 시장: Mark의 총 보수(USD1.42M)는 US 시장에서 비슷한 규모 기업의 평균(USD649.34K)보다 높습니다.

보상과 수익: Mark의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Mark Litton (57 yo)

4.6yrs

재임 기간

US$1,423,815

보수

Dr. Mark J. Litton, Ph D., MBA, serves as Director at Lumen Bioscience, Inc. since October 2020. He served as Chief Operating Officer of LeonaBio, Inc. (formerly known as Athira Pharma, Inc.) since July 20...

리더십 팀

이름	직위	재임 기간	보수	지분
Mark Litton	President	4.6yrs	US$1.42m	0.64% $ 604.3k
Mark Worthington	General Counsel	4.9yrs	US$731.48k	0.20% $ 185.4k
Javier San Martin	Chief Medical Officer	2.1yrs	US$810.14k	0.17% $ 160.3k
Robert Renninger	Chief Financial Officer	1.6yrs	데이터 없음	0.17% $ 159.9k
Kevin Church	Chief Scientific Officer	3.3yrs	US$1.34m	0.27% $ 254.0k
Julie Rathbun	Head of Investor Relations	no data	데이터 없음	데이터 없음
Mark F. Kubik	Chief Business Officer	less than a year	데이터 없음	데이터 없음

2.7yrs

평균 재임 기간

58yo

평균 나이

경험이 풍부한 관리: LONA의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.7 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Mark Litton	President	4.6yrs	US$1.42m	0.64% $ 604.3k
Grant Pickering	Independent Director	4.3yrs	US$50.16k	0.027% $ 26.0k
Kelly Romano	Independent Chairwoman of the Board	5.4yrs	US$90.66k	0.086% $ 81.4k
Joseph Edelman	Independent Director	6yrs	US$49.16k	0% $ 0
Hans Moebius	Member of Scientific Advisory Board	3.9yrs	US$1.29m	데이터 없음
Marwan Sabbagh	Member of Scientific Advisory Board	3.9yrs	데이터 없음	데이터 없음
Barbara Kosacz	Independent Director	5.2yrs	US$59.16k	0% $ 0
Pierre Tariot	Member of Scientific Advisory Board	3.9yrs	데이터 없음	데이터 없음
Michael A. Panzara	Independent Director	4.2yrs	US$59.16k	0% $ 0
James Johnson	Independent Director	5.8yrs	US$70.16k	0.0053% $ 5.0k
John Olichney	Member of Scientific Advisory Board	3.9yrs	데이터 없음	데이터 없음
Anton Porsteinsson	Member of Scientific Advisory Board	3.9yrs	데이터 없음	데이터 없음

4.3yrs

평균 재임 기간

63yo

평균 나이

경험이 풍부한 이사회: LONA의 이사회는 경험이 있음으로 간주됩니다(평균 재임 4.3 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/21 00:31
종가	2026/05/20 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

LeonaBio, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Esther Lannie Hong	Berenberg
Eric Schmidt	Cantor Fitzgerald & Co.
Jason Butler	Citizens JMP Securities, LLC

LeonaBio 경영진

경영진 기준 점검 3/4

핵심 정보

최근 경영진 업데이트

Insufficient new directors

LeonaBio, Inc., Annual General Meeting, Jun 22, 2026

Leonabio, Inc. Announces the Appointment of Mark F. Kubik as Chief Business Officer

Insufficient new directors

Athira Pharma, Inc., Annual General Meeting, May 29, 2025

High number of new directors

Recent updates

Price target increased by 60% to US$16.00

Insufficient new directors

LeonaBio, Inc., Annual General Meeting, Jun 22, 2026

LeonaBio, Inc. announced that it has received $89.724073 million in funding

Leonabio, Inc. Announces the Appointment of Mark F. Kubik as Chief Business Officer

Athira Pharma, Inc. Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate

New major risk - Share price stability

Athira Pharma, Inc. announced that it expects to receive $89.724073 million in funding

Insufficient new directors

New minor risk - Share price stability

Athira Pharma, Inc., Annual General Meeting, May 29, 2025

New major risk - Market cap size

High number of new directors

Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Price target decreased by 46% to US$4.00

Athira Pharma, Inc. Announces Topline Results from Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Athira Pharma Announces Last Patient Completed Lift-Ad Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer’s Disease

New major risk - Financial position

Independent Chairwoman of the Board recently bought US$100k worth of stock

Athira Pharma, Inc. Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer

Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Athira Pharma, Inc., Annual General Meeting, May 23, 2024

New minor risk - Market cap size

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer

Price target increased by 23% to US$9.25

Athira Pharma, Inc. Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-B-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

New minor risk - Market cap size

Athira Pharma, Inc. Appoints Andrew Gengos as Chief Financial Officer

Athira Pharma, Inc. Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease

CFO & Chief Business Officer recently bought US$192k worth of stock

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Athira Pharma, Inc. Announces the Appointment of Andrew Gengos as Chief Business Officer

Athira Pharma, Inc. Announces CFO Changes

Independent Director recently bought US$60k worth of stock

Price target decreased by 33% to US$7.83

Athira Pharma Announces Promotion of Kevin Church to Chief Scientific Officer

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Chief Financial Officer recently bought US$142k worth of stock

Athira Pharma, Inc. Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

Independent Chairwoman of the Board recently bought US$99k worth of stock

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Price target increased to US$11.75

High number of new and inexperienced directors

Athira Pharma Advances Phase 2/3 Lift-Ad Clinical Study of Fosgonimeton in Mild-To Moderate Alzheimer's Patients Following Independent, Unblinded Interim Analysis

Price target increased to US$11.75

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Athira Pharma, Inc. Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients

Athira Pharma GAAP EPS of -$0.65

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022

Price target decreased to US$15.40

Athira Pharma, Inc. Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Athira Pharma, Inc. Announces New Board Appointments

Richard A Kayne Issues Letter to Shareholders of Athira Pharma Inc

Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

Richard A Kayne Communicates with Athira Pharma Inc

High number of new and inexperienced directors

Richard A. Kayne Files an Investor Presentation to Shareholders of Athira Pharma

Richard A. Kayne Provides Information to Shareholders of Athira Pharma Inc

Athira Pharma, Inc., Annual General Meeting, May 19, 2022

Athira Pharma, Inc. Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions

Independent Chairman of the Board recently bought US$105k worth of stock